Model screening for oral cavity and pharyngeal cancer in Hungary

2001 ◽  
Vol 37 ◽  
pp. S238
Author(s):  
P. Koltai ◽  
É. Remenár ◽  
M. Fülöp ◽  
F. Oberna ◽  
K. Pólus
Author(s):  
E. S. Sedova ◽  
V. I. Jusupov ◽  
N. N. Vorobieva ◽  
N. V. Kanischeva ◽  
A. A. Chernyavskii ◽  
...  

Low-level laser therapy as a method for correcting the mucositis caused by ionizing radiation of the oral mucosa is used in clinical practice for various exposure parameters: radiation power not less than 10 mW, laser doses not less than 2 J/cm2. The purpose of this study was to compare the efficacy of low-level laser therapyred and infrared laser radiation for the correction of mucositis of the oral mucosa in patients receiving radiation and chemoradiotherapy for oral and pharyngeal cancer, with laser doses of less than 1 J/cm2. The study included 106 patients who received radiation and chemoradiotherapy for cancer of the oral cavity and pharynx, which were randomly divided into three groups. In the first (37 patients), mucositis was prevented and corrected in accordance with the standards of the clinic, in the second (36 patients) and the third (33 patients), patients were additionally exposed to the oral cavity with Low-level laser therapy (LLLT) at 635 nm and 780 nm at powers of 5 mW and 20 mW, respectively. The effect of LLLT on the wavelength of 635 nm significantly reduced the frequency and severity of mucositis, increased the time until the appearance of the first symptoms of mucositis of the oral mucosa, shortened the duration of severe mucositis (grade 3), and reduced the need for painkillers, including narcotic analgesics compared with the group who received standard prophylaxis and correction of mucositis.


Author(s):  
W.B. Garner ◽  
D. Edmonston ◽  
D.V. Wakefield ◽  
G.R. Williams ◽  
M. Fenton ◽  
...  

2018 ◽  
Vol 27 (2) ◽  
pp. 171-179 ◽  
Author(s):  
Yuquan Lu ◽  
Tomotaka Sobue ◽  
Tetsuhisa Kitamura ◽  
Ryoichi Matsuse ◽  
Yuri Kitamura ◽  
...  

2016 ◽  
Vol 48 (12) ◽  
pp. 1544-1550 ◽  
Author(s):  
Corina Lesseur ◽  
Brenda Diergaarde ◽  
Andrew F Olshan ◽  
Victor Wünsch-Filho ◽  
Andrew R Ness ◽  
...  

1996 ◽  
Vol 20 (7) ◽  
pp. 1206-1210 ◽  
Author(s):  
K. Jokelainen ◽  
E. Heikkonen ◽  
R. Roine ◽  
H. Lehtonen ◽  
M. Salaspuro

2010 ◽  
Vol 1 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Chaturvedi Pankaj

Abstract A lesser known reason of epidemic proportion of oral cancer in India is the rampant use of Areca nut chewing. Just like tobacco, areca nut or betel nut is a psychostimulant, an addictive substance and a carcinogen. The cancer causing properties of areca nut have been well-reported in animal, human and epidemiologic studies. The World Health Organization and International Agency for Research on cancer classified areca nut as a Group 1 human carcinogens with sufficient evidence of increased risk of submucus fibrosis (precancerous oral lesion) and cancers of the oral cavity, pharynx, and esophagus. This was based upon several studies from India, Bangladesh, Pakistan and Taiwan. Cancers caused by betel nut chewing also shows a strong dose–response relationship for frequency and duration of chewing. It is postulated that areca nut-specific N-nitroso compounds converted from alkaloids are responsible for oral and pharyngeal cancer. There are several other reports that have linked areca nut chewing (with or without tobacco) with hepatocellular carcinoma, cholangiocarcinoma, cancers of the larynx, stomach, lung and cervix in humans.


2014 ◽  
Vol 40 (4) ◽  
pp. 420-427 ◽  
Author(s):  
Nadine SM Offermans ◽  
Roel Vermeulen ◽  
Alex Burdorf A ◽  
R Alexandra Goldbohm ◽  
András P Keszei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document